Managers / Q2 2020 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$302M
Q2 2020
Positions
52
Filings on Record
30
2019–present window
Filed
Aug 14, 2020
original filing
Summary
Sivik Global Healthcare LLC reported $302M in U.S.-listed holdings across 52 positions for Q2 2020.
Its largest position, DGX, represents 4.7% of the portfolio.
Compared with Q1 2020, the fund opened 24 new positions and exited 11.
Portfolio Metrics
Turnover
+31.3%
vs prior filed quarter
Top-10 Concentration
+35.6%
share of reported value
Largest Position
+4.7%
Quest Diagnostics
New / Exited
24 / 11
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 84.0% · $254M
- ADR · 11.4% · $34M
- Other · 4.6% · $14M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DGXQuest Diagnostics Inc | NEW | +125.0K | 125.0K | +$14M | $14M |
| Laboratory Corp of America Ho | NEW | +60.0K | 60.0K | +$10M | $10M |
| Hologic Inc | NEW | +100.0K | 100.0K | +$6M | $6M |
| MDTMedtronic PLC | NEW | +60.0K | 60.0K | +$6M | $6M |
| LHC Group Inc | NEW | +30.0K | 30.0K | +$5M | $5M |
| AMEDAmedisys Inc | NEW | +25.0K | 25.0K | +$5M | $5M |
| Nevro Corp | NEW | +40.0K | 40.0K | +$5M | $5M |
| MOHMolina Healthcare Inc | NEW | +26.0K | 26.0K | +$5M | $5M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
52 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | DGXQuest Diagnostics Inchistory → | Cash Securities | 4.72% | $14M | 125.0K |
| 2 | HUMDanaher Corphistory → | Cash Securities | 3.95% | $12M | 67.5K |
| 3 | MCKThermo Fisher Scientific Inchistory → | Cash Securities | 3.90% | $12M | 32.5K |
| 4 | SNNHCA Healthcare Inchistory → | Cash Securities | 3.86% | $12M | 120.0K |
| 5 | Laboratory Corp of America Ho | Cash Securities | 3.30% | $10M | 60.0K |
| 6 | SYKEli Lilly and Cohistory → | Cash Securities | 3.26% | $10M | 60.0K |
| 7 | CORHumana Inchistory → | Cash Securities | 3.21% | $10M | 25.0K |
| 8 | HCAAbbott Laboratorieshistory → | Cash Securities | 3.18% | $10M | 105.0K |
| 9 | HRCZimmer Biomet Holdings Inchistory → | Cash Securities | 3.16% | $10M | 80.0K |
| 10 | REGNRegeneron Pharmaceuticals Inchistory → | Cash Securities | 3.10% | $9M | 15.0K |
| 11 | INCYUniversal Health Services Inchistory → | Cash Securities | 3.08% | $9M | 100.0K |
| 12 | AZNNMcKesson Corphistory → | Cash Securities | 3.05% | $9M | 60.0K |
| 13 | CNCCardinal Health Inchistory → | Cash Securities | 2.94% | $9M | 170.0K |
| 14 | S24Catalent Inchistory → | Cash Securities | 2.79% | $8M | 115.0K |
| 15 | DHRAmerisourceBergen Corphistory → | Cash Securities | 2.67% | $8M | 80.0K |
| 16 | NVOBoston Scientific Corphistory → | Cash Securities | 2.44% | $7M | 210.0K |
| 17 | ISRGTenet Healthcare Corphistory → | Cash Securities | 2.40% | $7M | 400.0K |
| 18 | CAHBaxter International Inchistory → | Cash Securities | 2.14% | $6M | 75.0K |
| 19 | CIStryker Corphistory → | Cash Securities | 2.09% | $6M | 35.0K |
| 20 | ABBVBio-Rad Laboratories Inchistory → | Cash Securities | 1.94% | $6M | 13.0K |
| 21 | Hologic Inc | Cash Securities | 1.89% | $6M | 100.0K |
| 22 | VRTXCigna Corphistory → | Cash Securities | 1.86% | $6M | 30.0K |
| 23 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 1.84% | $6M | 45.0K |
| 24 | MDTMedtronic PLChistory → | Cash Securities | 1.82% | $6M | 60.0K |
| 25 | MRKEncompass Health Corphistory → | Cash Securities | 1.74% | $5M | 85.0K |
| 26 | LHC Group Inc | Cash Securities | 1.73% | $5M | 30.0K |
| 27 | AMEDAmedisys Inchistory → | Cash Securities | 1.64% | $5M | 25.0K |
| 28 | Nevro Corp | Cash Securities | 1.58% | $5M | 40.0K |
| 29 | MOHMolina Healthcare Inchistory → | Cash Securities | 1.53% | $5M | 26.0K |
| 30 | ZBHCharles River Laboratories Inhistory → | Cash Securities | 1.44% | $4M | 25.0K |
| 31 | BDXBecton Dickinson and Cohistory → | Cash Securities | 1.41% | $4M | 17.8K |
| 32 | JNJJohnson & Johnsonhistory → | Cash Securities | 1.40% | $4M | 30.0K |
| 33 | TMOSmith & Nephew PLChistory → | Cash Securities | 1.34% | $4M | 106.1K |
| 34 | PPD Inc | Cash Securities | 1.33% | $4M | 150.0K |
| 35 | BIIBBiogen Inchistory → | Cash Securities | 1.33% | $4M | 15.0K |
| 36 | GILDGilead Sciences Inchistory → | Cash Securities | 1.27% | $4M | 50.0K |
| 37 | THCSTERIS PLChistory → | Cash Securities | 1.27% | $4M | 25.0K |
| 38 | BMYCentene Corphistory → | Cash Securities | 1.26% | $4M | 60.0K |
| 39 | ILMNIllumina Inchistory → | Cash Securities | 1.23% | $4M | 10.0K |
| 40 | TEVATeva Pharmaceutical Industriehistory → | Cash Securities | 1.12% | $3M | 275.0K |
| 41 | AVTRAvantor Inc | Cash Securities | 0.99% | $3M | 175.0K |
| 42 | AMRXAmneal Pharmaceuticals Inc | Cash Securities | 0.95% | $3M | 600.0K |
| 43 | BNTXBioNTech SE | Cash Securities | 0.88% | $3M | 40.0K |
| 44 | BMRNSelect Medical Holdings Corp | Cash Securities | 0.85% | $3M | 175.0K |
| 45 | ADPTAdaptive Biotechnologies Corp | Cash Securities | 0.80% | $2M | 50.0K |
| 46 | ACHOwens & Minor Inc | Cash Securities | 0.75% | $2M | 298.7K |
| 47 | CRSPCRISPR Therapeutics AG | Cash Securities | 0.73% | $2M | 30.0K |
| 48 | AGIOAgios Pharmaceuticals Inc | Cash Securities | 0.71% | $2M | 40.0K |
| 49 | Bluebird Bio Inc | Cash Securities | 0.71% | $2M | 35.0K |
| 50 | ABTMerck & Co Inc | Cash Securities | 0.64% | $2M | 25.0K |
| 51 | CNSTConstellation Pharmaceuticals | Cash Securities | 0.60% | $2M | 60.0K |
| 52 | Eiger BioPharmaceuticals Inc | Cash Securities | 0.14% | $423,000 | 44.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.